Long-acting injectable cabotegravir for PrEP well tolerated in HPTN 077

(FHI360) Study results released today by the HIV Prevention Trials Network (HPTN) show long-acting injectable cabotegravir (CAB LA) to be well tolerated by men and women and support the dosing schedule currently being used in a phase 3 HPTN study for HIV prevention.